IMDX compared with LCTX: revenue, margins and what each company keeps, and the suppliers and customers both name

IMDXInsight Molecular Diagnostics Inc.

Mkt capRevenueRevenue

LCTXLineage Cell Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

IMDXInsight Molecular Diagnostics Inc.

LCTXLineage Cell Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

IMDX1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±70.8%▼−7.13%×0.10

LCTX1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−2.65%—

= impliedIMDX realized, solidLCTX realized, hatchedOne scale, both sides: full bar = 71%× = |realized| ÷ impliedSource: market data

IMDXInsight Molecular Diagnostics Inc.

2.90▼−2.03%

Mkt cap$96.9MRevenue$239,000Q2 FY26Revenue$4MFY25

LCTXLineage Cell Therapeutics, Inc.

1.00▲+0.48%

Regular sessionNov 2 '26

Mkt cap$252.9MRevenue$1MQ2 FY26Revenue$15MFY25

Compare

Regular sessionNov 2 '26

IMDXInsight Molecular Diagnostics Inc.

LCTXLineage Cell Therapeutics, Inc.

2.90▼−2.03%

Price

1.00▲+0.48%

$96.9M

Mkt cap

$252.9M

Q2 FY26$239,000

Revenue

$1MQ2 FY26

FY25$4M

Revenue

$15MFY25

IMDX2.90▼−2.03%vsLCTX1.00▲+0.48%Regular sessionNov 2 '26